Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA).  At least one portion of the meeting will be closed to the public.

*Name of Committee*:  Vaccines and Related Biological Products Advisory Committee.                

*General Function of the Committee*:   To provide advice and recommendations to the agency on FDA's regulatory issues.                

*Date and Time*:   The meeting will be held on January 25, 2007, from 8 a.m. to 5 p.m.                

*Location*:   Doubletree Hotel, 8120 Wisconsin Ave., Bethesda, MD  20814.                

*Contact Person*:  Christine Walsh or Denise Royster, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration,  1401 Rockville Pike, Rockville, MD 20852,  301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512391.  Please call the Information Line for up-to-date information on this meeting.                

*Agenda*:   In Session I, the committee will hear presentations and make recommendations on the safety and immunogenicity of PENTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis  Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib)), manufactured by Sanofi Pasteur, Ltd.  In Session II, the committee will hear an overview of the research programs in the Office of Vaccines Research and Review, Center for Biologics Evaluation and Research (CBER).  In the closed session, the committee will discuss the                           ( print page 969)                        report of the Office of Vaccines Research and Review Office Site Visit of May 19, 2006.                

                    FDA intends to make background material available to the public no later than 1 business day before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.  Background material is available at                     *http://www.fda.gov/​ohrms/​dockets/​ac/​acmenu.htm*.  Click on the year 2007 and scroll down to the appropriate advisory committee link.                

*Procedure*: On January 25, 2007, from 8 a.m. to 4:25 p.m., the meeting is open to the public.  Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.  Written submissions may be made to the contact person on or before January 19, 2007.  Oral presentations from the public will be scheduled between approximately 11:15 a.m. to 11:45 a.m. and 3:55 p.m. to 4:25 p.m.  Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before January 11, 2007.  Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by January 12, 2007.                

*Closed Committee Deliberations*:   On January 25, 2007, from 4:25 p.m. to 5 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)).  The committee will discuss the report of the May 19, 2006, review of internal research programs in the Office of Vaccines Research and Review, Division of Viral Products and Division of Bacterial, Parasitic, and Allergenic Products, CBER.                

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Christine Walsh or Denise Royster at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 3, 2007.

Randall W. Lutter,

Associate Commissioner for Policy and Planning.

[FR Doc. 07-28 Filed 1-4-07; 8:45 am]

BILLING CODE 4160-01-S